Cargando…
A novel isoflavone, ME-344, targets the cytoskeleton in acute myeloid leukemia
The isoflavone ME-344 is a potent anti-cancer agent with preclinical and clinical efficacy in solid tumors. Yet, the mechanism of action of ME-344 has not been fully defined and the preclinical efficacy in leukemia has not been established. Therefore, we investigated the anti-leukemic properties and...
Autores principales: | Jeyaraju, Danny V., Hurren, Rose, Wang, Xiaoming, MacLean, Neil, Gronda, Marcela, Shamas-Din, Aisha, Minden, Mark D., Giaever, Guri, Schimmer, Aaron D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226547/ https://www.ncbi.nlm.nih.gov/pubmed/27391350 http://dx.doi.org/10.18632/oncotarget.10446 |
Ejemplares similares
-
The thymidine dideoxynucleoside analog, alovudine, inhibits the mitochondrial DNA polymerase γ, impairs oxidative phosphorylation and promotes monocytic differentiation in acute myeloid leukemia
por: Yehudai, Dana, et al.
Publicado: (2019) -
A Phase 1 study of intravenous infusions of tigecycline in patients with acute myeloid leukemia
por: Reed, Gregory A., et al.
Publicado: (2016) -
Ibrutinib synergizes with poly(ADP-ribose) glycohydrolase inhibitors to induce cell death in AML cells via a BTK-independent mechanism
por: Rotin, Lianne E., et al.
Publicado: (2015) -
Voltage-Dependent Anion Channels Influence Cytotoxicity of ME-344, a Therapeutic Isoflavone
por: Zhang, Leilei, et al.
Publicado: (2020) -
Inhibition of SREBP1 sensitizes cells to death ligands
por: Eberhard, Yanina, et al.
Publicado: (2011)